Janux Therapeutics, Inc. (JANX) — 8-K Filings

8-K Filings (10)

• Janux Therapeutics Announces Board and Compensation Changes — Sep 19, 2025 Risk: medium
  On September 18, 2025, Janux Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates
• Janux Therapeutics Files 8-K on Shareholder Vote Matters — Jun 13, 2025 Risk: low
  On June 11, 2025, Janux Therapeutics, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing, submitted on J
• Janux Therapeutics Files 8-K — Dec 5, 2024 Risk: low
  On December 4, 2024, Janux Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specifi
• Janux Therapeutics Files 8-K — Dec 2, 2024 Risk: low
  On December 2, 2024, Janux Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and
• Janux Therapeutics Appoints New CMO and CDO — Jul 22, 2024 Risk: medium
  On July 19, 2024, Janux Therapeutics, Inc. announced the appointment of Dr. David M. Epstein as Chief Medical Officer and Dr. Robert J. Smith as Chief Developme
• Janux Therapeutics Files 8-K on Security Holder Vote Matters — Jun 28, 2024 Risk: low
  On June 26, 2024, Janux Therapeutics, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The company, incorporated
• Janux Therapeutics Files 8-K Report — Feb 29, 2024 Risk: low
  On February 28, 2024, Janux Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with n
• Janux Therapeutics Files Routine 8-K — Feb 28, 2024 Risk: low
  Janux Therapeutics, Inc. filed an 8-K on February 28, 2024, under the 'Other Events' category. The filing indicates a routine current report pursuant to Section
• Janux Therapeutics Files Generic 8-K for 'Other Event' — Feb 27, 2024 Risk: low
  Janux Therapeutics, Inc. filed an 8-K form with the SEC on February 27, 2024, reporting an "Other Event." This filing, identified by accession number 0000950170
• Janux Therapeutics Files 8-K for Regulation FD Disclosure — Feb 26, 2024 Risk: low
  Janux Therapeutics, Inc. filed an 8-K on February 26, 2024, to disclose information under Regulation FD and provide financial statements and exhibits. The filin

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX